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Introduction
Systemic-onset juvenile idiopathic arthritis (sjia) is a
form of childhood chronic arthritis of unknown etiology
with systemic manifestations such as remittent fever and
erythematous rash, lymph adenopathy, hepatosplenome-
galy, and/or serositis. Tocilizumab (TCZ) is a huma-
nized anti-IL-6 receptor monoclonal antibody that has
been approved for the treatment of patients with sjia.
Results of the lead-in phase; the placebo-controlled,
double-blind phase; and the first 48 weeks of an open-
label extension have been already published.
Objectives
To assess the long-term safety and effecacy of tocilizu-
mab in sjia.
Methods
The long-term extension phase of two pivotal studies
(Phase II study with 11 patients and Phase III study
with 56 patients) in patients with active sjia was ana-
lyzed. Patients received open-label tocilizumab (8 mg/
kg, every 2 wks). Assessments included ACR Pedi 30/
50/70 responses, adverse events (aes), laboratory para-
meters, oral corticosteroid dose reductions, and growth
rates (the latter compared with national standards).
Results
In total, 67 patients were enrolled. Median duration of
exposure was 3.4 years. Event rates of aes and serious
aes were 803.7/100 patient-years (pys) and 34.7/100 pys,
respectively. The most common serious aes were infec-
tions (13.2/100 pys). Mean liver enzyme levels basically
remained stable over the course of the study. Grade 3
elevations in alanine and aspartate aminotransferase
levels occurred in six (9.0%) and four (6.0%) patients,
respectively. Mean total cholesterol levels also were not
increased during the study, although eight (11.9%)
patients experienced grade 2 elevations in total choles-
terol. ACR Pedi response rates were maintained
throughout the study: at week 168, ACR Pedi 30/50/70
response rates were 80.3%, 80.3%, and 75.4%, respec-
tively. Tocilizumab completely blocked the production
of C-reactive protein and serum amyloid A in sjia.
Twenty-two (32.8%) patients discontinued corticoster-
oids during tocilizumab therapy. Of 52 patients com-
pleting the week 168 visit, 40 (76.9%) reduced
corticosteroid doses by at least 50%, and 33 (63.5%)
patients by 70%. Significant improvement was seen in
changes in height velocity (HV) SDS from 1 year prior
to 1 year after baseline. HV-SDS continued to improve
through the studies of toiclizumab treatment.
Conclusion
Tocilizumab had an acceptable safety profile, was asso-
ciated with sustained clinical improvement, and reduced
systemic corticosteroid dose in children with sjia. Also,
catch-up growth was observed in patients under the
treatment with tocilizumab.
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